Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Ublituximab was generally well tolerated, with no unexpected safety signals
BLA submission targeted in Q3 2021
Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET
Live Webcast: http://ir.tgtherapeutics.com/events (also archived for future review)
https://finance.yahoo.com/news/tg-therapeutics-announces-positive-results-113000006.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.